Tacrolimus — Veterinary Vademecum Drug Reference

Dosage & Administration Guidelines

Species	Route	Dose	Frequency	Duration & Clinical Notes
Dog	Topical (ointment 0.1%)	Thin film applied to affected areas	Every 12 hours initially, then taper to every 24-48 hours	Duration: Variable; often 4-6 weeks for atopic dermatitis, longer for perianal fistulas Notes: Apply to clean, dry skin; avoid contact with eyes and mucous membranes. For perianal fistulas, apply to fistulous tracts after cleaning.
Dog	Oral (capsules or compounded suspension)	0.1-0.3 mg/kg	Every 12 hours	Duration: Variable; often 2-4 weeks for induction, then taper to lowest effective dose Notes: Start at low end and titrate based on response and trough levels (target 5-20 ng/mL). Monitor renal function and blood pressure.
Dog	Ophthalmic (0.03% or 0.1% ointment)	1/4 to 1/2 inch ribbon into affected eye	Every 12 hours	Duration: Long-term; may be tapered to once daily Notes: For keratoconjunctivitis sicca, may take 4-6 weeks to see improvement. Monitor tear production.
Cat	Topical (ointment 0.1%)	Thin film applied to affected areas	Every 12 hours, then taper	Duration: Variable; often 4-6 weeks Notes: Apply to clean, dry skin; avoid licking immediately after application.
Cat	Oral (capsules or compounded suspension)	0.1-0.3 mg/kg	Every 12 hours	Duration: Variable; often 2-4 weeks for induction, then taper Notes: Monitor trough levels (target 5-20 ng/mL). Use with caution in renal disease.
Horse	Ophthalmic (0.03% or 0.1% ointment)	1/2 inch ribbon into affected eye	Every 6-12 hours	Duration: Long-term; may be tapered Notes: For recurrent uveitis and immune-mediated keratitis. Monitor intraocular pressure.
Rabbit	Topical (ointment 0.1%)	Thin film applied to affected areas	Every 12 hours	Duration: Variable Notes: Use with caution; rabbits may ingest topically applied drug.

Clinical Indications & Species Uses

General Indications

Immunosuppressive therapy for various immune-mediated diseases
Topical treatment for inflammatory skin conditions
Ophthalmic use for immune-mediated ocular diseases

Dog (Canine)

Atopic dermatitis (topical, as 0.1% ointment)
Perianal fistulas (topical or systemic)
Immune-mediated diseases (e.g., immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, inflammatory bowel disease, lupus, pemphigus) as a steroid-sparing agent
Keratoconjunctivitis sicca (dry eye) (topical ophthalmic)
Corneal graft rejection (topical ophthalmic)
Systemic lupus erythematosus (off-label)
Myasthenia gravis (off-label, immunosuppressive therapy)

Cat (Feline)

Atopic dermatitis (topical, as 0.1% ointment)
Eosinophilic granuloma complex (topical or systemic)
Immune-mediated diseases (e.g., inflammatory bowel disease, immune-mediated hemolytic anemia) as a steroid-sparing agent
Feline asthma (systemic, off-label)
Keratoconjunctivitis sicca (topical ophthalmic)

Horse (Equine)

Equine recurrent uveitis (topical ophthalmic)
Immune-mediated keratitis (topical ophthalmic)
Dermatitis (topical, off-label)

Rabbit & Small Mammals

Dermatitis (topical, off-label)
Immune-mediated diseases (systemic, off-label)

Exotic & Other Species

Reptiles: Dermatitis (topical, off-label)
Small mammals (ferrets, guinea pigs): Immune-mediated diseases (systemic, off-label)

Pharmacology & Mechanism of Action

Drug Class: Calcineurin inhibitor | Pharmacological Group: Immunosuppressant / Topical immunomodulator

Mechanism of Action: Tacrolimus binds to FK506-binding protein (FKBP-12), forming a complex that inhibits calcineurin phosphatase activity. This prevents dephosphorylation and nuclear translocation of nuclear factor of activated T-cells (NFAT), thereby inhibiting transcription of pro-inflammatory cytokines such as IL-2, IL-3, IL-4, IL-5, IFN-γ, and TNF-α. It also suppresses mast cell degranulation and inhibits release of histamine and other inflammatory mediators, and downregulates expression of high-affinity IgE receptors on mast cells and basophils. In T-cells, it blocks cell cycle progression at G0/G1 phase, leading to immunosuppression.

Pharmacodynamics: Tacrolimus is a potent immunosuppressant with activity 10-100 times greater than cyclosporine in vitro. It inhibits T-cell activation and proliferation, reduces cytokine production, and suppresses both humoral and cell-mediated immune responses. Topically, it reduces pruritus and inflammation in allergic dermatitis by modulating local immune responses. It also inhibits release of preformed and newly synthesized mediators from mast cells and basophils. Systemic use leads to profound immunosuppression, affecting both primary and secondary immune responses.

⚡ Pharmacokinetics Summary

Absorption: Oral absorption is incomplete and variable, with bioavailability approximately 25% in dogs and 30% in cats. Food decreases the rate and extent of absorption, especially high-fat meals. Topical absorption is minimal (<5%) when applied to intact skin, but may increase with inflamed or damaged skin. In humans, peak blood concentrations occur 1-3 hours after oral administration.

Distribution: Tacrolimus is extensively distributed in tissues, with a large volume of distribution (Vd) of about 0.9-1.5 L/kg in dogs. It crosses the placenta and is excreted in milk. It binds to erythrocytes and lipoproteins in blood; whole blood concentrations are higher than plasma concentrations. Protein binding is approximately 75-99% in plasma, mainly to albumin and alpha-1-acid glycoprotein.

Metabolism: Tacrolimus is extensively metabolized by hepatic and intestinal cytochrome P450 enzymes, primarily CYP3A4 and CYP3A5, and to a lesser extent by P-glycoprotein efflux. It undergoes O-demethylation and hydroxylation to form multiple metabolites, most of which are inactive. Metabolism is species-dependent; dogs and cats have similar pathways.

Excretion: The primary route of elimination is biliary excretion of metabolites into feces. Less than 1% of the parent drug is excreted unchanged in urine. In dogs, the elimination half-life is approximately 4-8 hours after IV administration, but may be longer after oral dosing due to prolonged absorption. In cats, half-life is approximately 8-12 hours.

Half-Life: Dogs: 4-8 hours (IV); Cats: 8-12 hours (oral); Humans: 12-16 hours

Bioavailability: Dogs: ~25% (oral); Cats: ~30% (oral); Topical: <5% (intact skin)

Protein Binding: 75-99% (plasma proteins, mainly albumin and alpha-1-acid glycoprotein)

Available Formulations & Strengths

Topical Ointment 0.03%, 0.1% (Topical)

Oral Capsule 0.5 mg, 1 mg, 5 mg (Oral)

Oral Compounded Suspension Various (e.g., 1 mg/mL) (Oral)

Ophthalmic Ointment 0.03%, 0.1% (Ophthalmic)

Injectable Solution (IV) 5 mg/mL (for human use; not commonly used in veterinary) (IV)

Contraindications & Clinical Warnings

Contraindications:

Hypersensitivity to tacrolimus or any component of the formulation
Concurrent use with cyclosporine (additive immunosuppression and nephrotoxicity)
Pregnancy (unless benefits outweigh risks; may cause fetal harm)
Lactation (excreted in milk; use with caution)
Known malignancy (immunosuppression may exacerbate)
Active infection (immunosuppression may worsen)

Warnings & Clinical Precautions:

Use with caution in patients with renal impairment; monitor renal function and blood pressure.
May increase risk of infections, including opportunistic infections.
Live vaccines should not be administered during therapy.
Topical use may cause transient burning or stinging at application site.
Systemic use requires monitoring of blood levels (trough) to avoid toxicity.
May cause hyperglycemia, especially in cats.
Use with caution in patients with hepatic impairment.
Avoid contact with eyes and mucous membranes when applying topically.
In food animals, withdrawal times must be observed; not approved for food animals.
May interact with drugs metabolized by CYP3A4; adjust doses accordingly.

Adverse Effects & Reactions

Common:

Gastrointestinal upset (vomiting, diarrhea, anorexia) with oral use
Burning or stinging at topical application site
Increased risk of infections
Hyperglycemia (especially in cats)
Nephrotoxicity (increased creatinine, decreased renal function)
Hypertension

Serious / Severe:

Renal failure (especially with systemic use)
Neurotoxicity (tremors, seizures, ataxia)
Severe immunosuppression leading to opportunistic infections
Lymphoproliferative disorders (with prolonged systemic use)
Anaphylaxis (rare)

Rare:

Hepatotoxicity
Cardiotoxicity (QT prolongation)
Seizures
Pancreatitis
Alopecia
Gingival hyperplasia

Key Drug Interactions

Interacting Drug / Class	Clinical Effect & Mechanism	Severity
Cyclosporine	Additive immunosuppression and nephrotoxicity; concurrent use is contraindicated.	High
Ketoconazole, Itraconazole, Fluconazole	Inhibit CYP3A4, increasing tacrolimus blood levels; reduce tacrolimus dose by 50-75%.	High
Erythromycin, Clarithromycin	Inhibit CYP3A4, increasing tacrolimus levels; monitor and adjust dose.	High
Rifampin	Induces CYP3A4, decreasing tacrolimus levels; may require increased dose.	High
Phenobarbital, Phenytoin	Induce CYP3A4, decreasing tacrolimus levels; monitor.	Moderate
NSAIDs (e.g., meloxicam, carprofen)	Additive nephrotoxicity; use with caution.	Moderate
Aminoglycosides (e.g., gentamicin)	Additive nephrotoxicity; avoid concurrent use.	High
Corticosteroids	Additive immunosuppression; monitor for infections.	Moderate
Grapefruit juice	Inhibits intestinal CYP3A4, increasing tacrolimus bioavailability; avoid concurrent administration.	Moderate

Overdose & Toxicity Management

Signs of Toxicity:

Nephrotoxicity (elevated creatinine, decreased urine output)
Neurotoxicity (tremors, seizures, ataxia)
Hyperglycemia
Gastrointestinal signs (vomiting, diarrhea)
Hypertension
Electrolyte disturbances (hyperkalemia, hypomagnesemia)

Emergency Treatment Protocol: There is no specific antidote. Treatment is symptomatic and supportive. For oral overdose, induce emesis if within 1-2 hours and administer activated charcoal. Provide IV fluids to maintain renal perfusion and correct electrolyte imbalances. Monitor renal function, blood glucose, and neurological status. In severe cases, consider hemodialysis or hemoperfusion (though tacrolimus is highly protein-bound and not significantly removed by dialysis). Discontinue drug and provide supportive care.

Food Animal Withdrawal Times

Tacrolimus is not approved for use in food animals. In the US, extra-label use in food animals is prohibited under AMDUCA due to lack of established withdrawal times and potential for human food safety concerns. If used in food animals, a prolonged withdrawal period (e.g., 30 days or more) should be considered, but no official withdrawal times are established.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light. Keep container tightly closed. Do not freeze. For compounded suspensions, follow manufacturer's storage instructions (usually refrigerated and stable for 30-60 days).

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use (oral capsules, topical ointment, ophthalmic ointment).

Extra-Label (Off-Label) Use: In the US, tacrolimus is not FDA-approved for veterinary use; however, it is legally used in animals under the Animal Medicinal Drug Use Clarification Act (AMDUCA) for non-food animals. Extra-label use in food animals is prohibited. In the EU, similar regulations apply under the cascade system. Veterinarians must follow prescribing guidelines and obtain informed consent.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Tacrolimus is a potent immunosuppressant used in veterinary medicine primarily as a topical treatment for atopic dermatitis and perianal fistulas in dogs, and for immune-mediated ocular diseases in horses. Systemic use is reserved for severe immune-mediated diseases that are refractory to corticosteroids or when steroid-sparing is needed. Due to its narrow therapeutic index and potential for toxicity, therapeutic drug monitoring is recommended for systemic therapy, targeting trough levels of 5-20 ng/mL in whole blood. Topical use is generally safe, but systemic absorption can occur through inflamed skin. In cats, hyperglycemia is a common adverse effect, so blood glucose should be monitored. Tacrolimus is a CYP3A4 substrate, so drug interactions are significant. It is contraindicated in food animals. Overall, tacrolimus is a valuable addition to the veterinary pharmacopeia, but requires careful patient selection and monitoring.

References & Literature

📚 Plumb's Veterinary Drug Handbook
📚 Papich Veterinary Pharmacology and Therapeutics
📚 Compendium of Veterinary Products (CVP)